Cargando…

Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma

Colorectal cancer (CRC) is one of the most lethal diseases with high morbidity and mortality worldwide. Clinically, tumors located in colon and rectum have diverse prognosis and therapeutic outcome. Here, we performed data mining derived from 20 CRC patient samples to compare proteomic difference be...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Jun-Ze, Liang, Xiao-Ling, Zhong, Li-Ye, Wu, Chu-Tian, Zhang, Jing, Wang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959172/
https://www.ncbi.nlm.nih.gov/pubmed/33732636
http://dx.doi.org/10.3389/fonc.2020.617890
_version_ 1783664921501761536
author Liang, Jun-Ze
Liang, Xiao-Ling
Zhong, Li-Ye
Wu, Chu-Tian
Zhang, Jing
Wang, Yang
author_facet Liang, Jun-Ze
Liang, Xiao-Ling
Zhong, Li-Ye
Wu, Chu-Tian
Zhang, Jing
Wang, Yang
author_sort Liang, Jun-Ze
collection PubMed
description Colorectal cancer (CRC) is one of the most lethal diseases with high morbidity and mortality worldwide. Clinically, tumors located in colon and rectum have diverse prognosis and therapeutic outcome. Here, we performed data mining derived from 20 CRC patient samples to compare proteomic difference between colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ). We found that differential expressed proteins (DEPs) upregulated in COAD were mainly enriched in immune response, moreover, higher immune scores were found in COAD than READ, as calculated by The Cancer Genome Atlas (TCGA) data. To identify the core protein of DEPs with high prognostic value for COAD, we performed topological overlap matrix (TOM) to investigate the hub proteins using 77 immune-relevant DEPs, and identified complement component 3 (C3) as the core protein in the immune-relevant DEPs matrix between the COAD and READ. Moreover, we found that C3 was up-regulated in COAD, and its expression was negatively associated with overall survival of COAD patients but not READ. In conclusion, we identified C3-mediated immune response as key feature to distinguish COAD and READ, and highlighted C3 as potential biomarker with high prognostic value for clinical application, which provided new clue for precise treatment of COAD.
format Online
Article
Text
id pubmed-7959172
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79591722021-03-16 Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma Liang, Jun-Ze Liang, Xiao-Ling Zhong, Li-Ye Wu, Chu-Tian Zhang, Jing Wang, Yang Front Oncol Oncology Colorectal cancer (CRC) is one of the most lethal diseases with high morbidity and mortality worldwide. Clinically, tumors located in colon and rectum have diverse prognosis and therapeutic outcome. Here, we performed data mining derived from 20 CRC patient samples to compare proteomic difference between colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ). We found that differential expressed proteins (DEPs) upregulated in COAD were mainly enriched in immune response, moreover, higher immune scores were found in COAD than READ, as calculated by The Cancer Genome Atlas (TCGA) data. To identify the core protein of DEPs with high prognostic value for COAD, we performed topological overlap matrix (TOM) to investigate the hub proteins using 77 immune-relevant DEPs, and identified complement component 3 (C3) as the core protein in the immune-relevant DEPs matrix between the COAD and READ. Moreover, we found that C3 was up-regulated in COAD, and its expression was negatively associated with overall survival of COAD patients but not READ. In conclusion, we identified C3-mediated immune response as key feature to distinguish COAD and READ, and highlighted C3 as potential biomarker with high prognostic value for clinical application, which provided new clue for precise treatment of COAD. Frontiers Media S.A. 2021-02-15 /pmc/articles/PMC7959172/ /pubmed/33732636 http://dx.doi.org/10.3389/fonc.2020.617890 Text en Copyright © 2021 Liang, Liang, Zhong, Wu, Zhang and Wang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liang, Jun-Ze
Liang, Xiao-Ling
Zhong, Li-Ye
Wu, Chu-Tian
Zhang, Jing
Wang, Yang
Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title_full Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title_fullStr Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title_full_unstemmed Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title_short Comparative Proteome Identifies Complement Component 3-Mediated Immune Response as Key Difference of Colon Adenocarcinoma and Rectal Adenocarcinoma
title_sort comparative proteome identifies complement component 3-mediated immune response as key difference of colon adenocarcinoma and rectal adenocarcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959172/
https://www.ncbi.nlm.nih.gov/pubmed/33732636
http://dx.doi.org/10.3389/fonc.2020.617890
work_keys_str_mv AT liangjunze comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma
AT liangxiaoling comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma
AT zhongliye comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma
AT wuchutian comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma
AT zhangjing comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma
AT wangyang comparativeproteomeidentifiescomplementcomponent3mediatedimmuneresponseaskeydifferenceofcolonadenocarcinomaandrectaladenocarcinoma